23 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 23 of 23 clinical reviews.
Clinical comparison of Ambien (zolpidem) and Belsomra (suvorexant) for insomnia, including how to switch safely, efficacy data, side-effect profiles, and which patients benefit most from each drug.
A direct cost, access, and clinical comparison of Ambien (zolpidem) and Dayvigo (lemborexant), including trial data, insurance coverage, DEA scheduling, and which drug fits which patient.
Dayvigo vs Ambien: no head-to-head trial exists. Both cut sleep onset similarly, but lemborexant has stronger sleep-maintenance and next-morning data.
A clinical comparison of zolpidem (Ambien) and lemborexant (Dayvigo) side effects, including next-day sedation, dependence risk, parasomnias, and tolerability data from key trials.
A comparison of zolpidem (Ambien) and lemborexant (Dayvigo) covering mechanism, efficacy, safety, and how to safely switch between them.
Clinical guide to switching between Ambien (zolpidem) and Lunesta (eszopiclone), including dose equivalence, tapering protocols, and head-to-head efficacy data for sleep onset and maintenance insomnia.
Compare the side-effect profiles of Ambien (zolpidem) and trazodone for insomnia. Review clinical trial data, next-day impairment risks, dependency potential, and tolerability differences.
A clinical comparison of zolpidem (Ambien) and trazodone for insomnia, including how to switch between them, efficacy data, side-effect profiles, and practical guidance for patients and prescribers.
A comparison of Belsomra (suvorexant) and Dayvigo (lemborexant) side-effect profiles, drawing on key trial data from Herring et al. and SUNRISE-1.
A head-to-head comparison of Belsomra (suvorexant) and Dayvigo (lemborexant) covering price, insurance formulary placement, patient assistance programs, efficacy data, and practical access strategies for insomnia treatment.
A clinical comparison of suvorexant (Belsomra) and lemborexant (Dayvigo) covering efficacy, safety, next-morning alertness, and a step-by-step protocol for switching between them.
A head-to-head comparison of Belsomra (suvorexant) and trazodone for insomnia, covering cost, insurance access, efficacy data, side effects, and switching protocols.
Evidence-based guide to switching between Belsomra (suvorexant) and trazodone for insomnia, covering pharmacology, wash-out timing, dose equivalence, and clinical protocols.
Compare the side-effect profiles of Dayvigo (lemborexant) and trazodone for insomnia. Evidence from SUNRISE-1 and clinical data on tolerability, next-day function, and safety risks.
Compare Dayvigo (lemborexant) and trazodone for insomnia treatment. Covers pricing, insurance coverage, efficacy data from SUNRISE-1 and off-label evidence, side effects, and access options.
Dayvigo vs trazodone: Dayvigo is an FDA-approved orexin blocker with SUNRISE trial data; trazodone is a low-cost off-label sedative. No cross-taper needed.
Eszopiclone causes an unpleasant taste in up to 34% of users; zolpidem carries higher next-morning impairment risk. Both share a 2019 FDA boxed warning.
A clinical comparison of Lunesta (eszopiclone) and Belsomra (suvorexant) covering mechanism, efficacy, side effects, and how to switch safely between these two insomnia medications.
Comparing eszopiclone (Lunesta) and lemborexant (Dayvigo) for insomnia treatment. Evidence-based analysis of sleep onset, maintenance, next-day function, and safety profiles from clinical trials.
Compare the side-effect profiles of Lunesta (eszopiclone) and trazodone for insomnia, including clinical trial data, tolerability differences, and practical switching guidance.
A clinical comparison of eszopiclone (Lunesta) and trazodone for insomnia, including the evidence base for combining them, pharmacology, switching protocols, and safety data prepared by the HealthRX.com Editorial Team.
A comparison of eszopiclone (Lunesta) and trazodone for insomnia, including how to switch between them, dosing, safety data, and which patients do better on each drug.
No head-to-head trial exists, but data suggest lemborexant may edge out suvorexant on next-morning alertness and sleep onset speed. See dosing and approval details.